ID   JAK2_HUMAN              Reviewed;        1132 AA.
AC   O60674; O14636; O75297;
DT   15-DEC-1998, integrated into UniProtKB/Swiss-Prot.
DT   24-JAN-2001, sequence version 2.
DT   10-MAY-2017, entry version 192.
DE   RecName: Full=Tyrosine-protein kinase JAK2;
DE            EC=2.7.10.2 {ECO:0000269|PubMed:7615558, ECO:0000269|PubMed:9618263};
DE   AltName: Full=Janus kinase 2;
DE            Short=JAK-2;
GN   Name=JAK2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, AND CATALYTIC ACTIVITY.
RX   PubMed=9618263; DOI=10.1006/bbrc.1998.8685;
RA   Saltzman A., Stone M., Franks C., Searfoss G., Munro R., Jaye M.,
RA   Ivashchenko Y.;
RT   "Cloning and characterization of human Jak-2 kinase: high mRNA
RT   expression in immune cells and muscle tissue.";
RL   Biochem. Biophys. Res. Commun. 246:627-633(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=9446644;
RA   Dalal I., Arpaia E., Dadi H., Kulkarni S., Squire J., Roifman C.M.;
RT   "Cloning and characterization of the human homolog of mouse Jak2.";
RL   Blood 91:844-851(1998).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND CHROMOSOMAL TRANSLOCATION WITH ETV6.
RX   PubMed=9326218;
RA   Peeters P., Raynaud S.D., Cools J., Wlodarska I., Grosgeorge J.,
RA   Philip P., Monpoux F., Van Rompaey L., Baens M., Van Den Berghe H.,
RA   Marynen P.;
RT   "Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-
RT   associated kinase JAK2 as a result of t(9;12) in a lymphoid and
RT   t(9;15;12) in a myeloid leukemia.";
RL   Blood 90:2535-2540(1997).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164053; DOI=10.1038/nature02465;
RA   Humphray S.J., Oliver K., Hunt A.R., Plumb R.W., Loveland J.E.,
RA   Howe K.L., Andrews T.D., Searle S., Hunt S.E., Scott C.E., Jones M.C.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Ashwell R.I.S.,
RA   Babbage A.K., Babbage S., Bagguley C.L., Bailey J., Banerjee R.,
RA   Barker D.J., Barlow K.F., Bates K., Beasley H., Beasley O., Bird C.P.,
RA   Bray-Allen S., Brown A.J., Brown J.Y., Burford D., Burrill W.,
RA   Burton J., Carder C., Carter N.P., Chapman J.C., Chen Y., Clarke G.,
RA   Clark S.Y., Clee C.M., Clegg S., Collier R.E., Corby N., Crosier M.,
RA   Cummings A.T., Davies J., Dhami P., Dunn M., Dutta I., Dyer L.W.,
RA   Earthrowl M.E., Faulkner L., Fleming C.J., Frankish A.,
RA   Frankland J.A., French L., Fricker D.G., Garner P., Garnett J.,
RA   Ghori J., Gilbert J.G.R., Glison C., Grafham D.V., Gribble S.,
RA   Griffiths C., Griffiths-Jones S., Grocock R., Guy J., Hall R.E.,
RA   Hammond S., Harley J.L., Harrison E.S.I., Hart E.A., Heath P.D.,
RA   Henderson C.D., Hopkins B.L., Howard P.J., Howden P.J., Huckle E.,
RA   Johnson C., Johnson D., Joy A.A., Kay M., Keenan S., Kershaw J.K.,
RA   Kimberley A.M., King A., Knights A., Laird G.K., Langford C.,
RA   Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C., Lloyd D.M.,
RA   Lovell J., Martin S., Mashreghi-Mohammadi M., Matthews L., McLaren S.,
RA   McLay K.E., McMurray A., Milne S., Nickerson T., Nisbett J.,
RA   Nordsiek G., Pearce A.V., Peck A.I., Porter K.M., Pandian R.,
RA   Pelan S., Phillimore B., Povey S., Ramsey Y., Rand V., Scharfe M.,
RA   Sehra H.K., Shownkeen R., Sims S.K., Skuce C.D., Smith M.,
RA   Steward C.A., Swarbreck D., Sycamore N., Tester J., Thorpe A.,
RA   Tracey A., Tromans A., Thomas D.W., Wall M., Wallis J.M., West A.P.,
RA   Whitehead S.L., Willey D.L., Williams S.A., Wilming L., Wray P.W.,
RA   Young L., Ashurst J.L., Coulson A., Blocker H., Durbin R.M.,
RA   Sulston J.E., Hubbard T., Jackson M.J., Bentley D.R., Beck S.,
RA   Rogers J., Dunham I.;
RT   "DNA sequence and analysis of human chromosome 9.";
RL   Nature 429:369-374(2004).
RN   [5]
RP   FUNCTION, CATALYTIC ACTIVITY, COFACTOR, INTERACTION WITH IFNGR2, AND
RP   PHOSPHORYLATION.
RX   PubMed=7615558; DOI=10.1074/jbc.270.29.17528;
RA   Sakatsume M., Igarashi K., Winestock K.D., Garotta G., Larner A.C.,
RA   Finbloom D.S.;
RT   "The Jak kinases differentially associate with the alpha and beta
RT   (accessory factor) chains of the interferon gamma receptor to form a
RT   functional receptor unit capable of activating STAT transcription
RT   factors.";
RL   J. Biol. Chem. 270:17528-17534(1995).
RN   [6]
RP   INTERACTION WITH IFNGR2, AND PHOSPHORYLATION.
RX   PubMed=7673114; DOI=10.1074/jbc.270.36.20915;
RA   Kotenko S.V., Izotova L.S., Pollack B.P., Mariano T.M., Donnelly R.J.,
RA   Muthukumaran G., Cook J.R., Garotta G., Silvennoinen O., Ihle J.N.;
RT   "Interaction between the components of the interferon gamma receptor
RT   complex.";
RL   J. Biol. Chem. 270:20915-20921(1995).
RN   [7]
RP   INTERACTION WITH SKB1.
RX   PubMed=10531356; DOI=10.1074/jbc.274.44.31531;
RA   Pollack B.P., Kotenko S.V., He W., Izotova L.S., Barnoski B.L.,
RA   Pestka S.;
RT   "The human homologue of the yeast proteins Skb1 and Hsl7p interacts
RT   with Jak kinases and contains protein methyltransferase activity.";
RL   J. Biol. Chem. 274:31531-31542(1999).
RN   [8]
RP   INTERACTION WITH STAM2.
RC   TISSUE=Fetal brain;
RX   PubMed=10899310; DOI=10.1016/S0014-5793(00)01760-9;
RA   Endo K., Takeshita T., Kasai H., Sasaki Y., Tanaka N., Asao H.,
RA   Kikuchi K., Yamada M., Chenb M., O'Shea J.J., Sugamura K.;
RT   "STAM2, a new member of the STAM family, binding to the Janus
RT   kinases.";
RL   FEBS Lett. 477:55-61(2000).
RN   [9]
RP   FUNCTION, AND INTERACTION WITH IL23R.
RX   PubMed=12023369; DOI=10.4049/jimmunol.168.11.5699;
RA   Parham C., Chirica M., Timans J., Vaisberg E., Travis M., Cheung J.,
RA   Pflanz S., Zhang R., Singh K.P., Vega F., To W., Wagner J.,
RA   O'Farrell A.-M., McClanahan T.K., Zurawski S., Hannum C., Gorman D.,
RA   Rennick D.M., Kastelein R.A., de Waal Malefyt R., Moore K.W.;
RT   "A receptor for the heterodimeric cytokine IL-23 is composed of IL-
RT   12Rbeta1 and a novel cytokine receptor subunit, IL-23R.";
RL   J. Immunol. 168:5699-5708(2002).
RN   [10]
RP   CHROMOSOMAL TRANSLOCATION WITH PCM1.
RX   PubMed=15805263; DOI=10.1158/0008-5472.CAN-04-4263;
RA   Reiter A., Walz C., Watmore A., Schoch C., Blau I., Schlegelberger B.,
RA   Berger U., Telford N., Aruliah S., Yin J.A., Vanstraelen D.,
RA   Barker H.F., Taylor P.C., O'Driscoll A., Benedetti F., Rudolph C.,
RA   Kolb H.-J., Hochhaus A., Hehlmann R., Chase A., Cross N.C.P.;
RT   "The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute
RT   leukemia that fuses PCM1 to JAK2.";
RL   Cancer Res. 65:2662-2667(2005).
RN   [11]
RP   CHROMOSOMAL TRANSLOCATION WITH PCM1.
RX   PubMed=16034466; DOI=10.1038/sj.leu.2403879;
RA   Murati A., Gelsi-Boyer V., Adelaide J., Perot C., Talmant P.,
RA   Giraudier S., Lode L., Letessier A., Delaval B., Brunel V., Imbert M.,
RA   Garand R., Xerri L., Birnbaum D., Mozziconacci M.-J., Chaffanet M.;
RT   "PCM1-JAK2 fusion in myeloproliferative disorders and acute erythroid
RT   leukemia with t(8;9) translocation.";
RL   Leukemia 19:1692-1696(2005).
RN   [12]
RP   CHROMOSOMAL TRANSLOCATION WITH PCM1.
RX   PubMed=16091753; DOI=10.1038/sj.onc.1208850;
RA   Bousquet M., Quelen C., De Mas V., Duchayne E., Roquefeuil B.,
RA   Delsol G., Laurent G., Dastugue N., Brousset P.;
RT   "The t(8;9)(p22;p24) translocation in atypical chronic myeloid
RT   leukaemia yields a new PCM1-JAK2 fusion gene.";
RL   Oncogene 24:7248-7252(2005).
RN   [13]
RP   CHROMOSOMAL TRANSLOCATION WITH PCM1.
RX   PubMed=16769584;
RA   Bacher U., Reiter A., Haferlach T., Mueller L., Schnittger S.,
RA   Kern W., Schoch C.;
RT   "A combination of cytomorphology, cytogenetic analysis, fluorescence
RT   in situ hybridization and reverse transcriptase polymerase chain
RT   reaction for establishing clonality in cases of persisting
RT   hypereosinophilia.";
RL   Haematologica 91:817-820(2006).
RN   [14]
RP   TISSUE SPECIFICITY, AND CHROMOSOMAL TRANSLOCATION WITH PCM1.
RX   PubMed=16424865; DOI=10.1038/sj.leu.2404104;
RA   Adelaide J., Perot C., Gelsi-Boyer V., Pautas C., Murati A.,
RA   Copie-Bergman C., Imbert M., Chaffanet M., Birnbaum D.,
RA   Mozziconacci M.-J.;
RT   "A t(8;9) translocation with PCM1-JAK2 fusion in a patient with T-cell
RT   lymphoma.";
RL   Leukemia 20:536-537(2006).
RN   [15]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=19783980; DOI=10.1038/nature08448;
RA   Dawson M.A., Bannister A.J., Gottgens B., Foster S.D., Bartke T.,
RA   Green A.R., Kouzarides T.;
RT   "JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from
RT   chromatin.";
RL   Nature 461:819-822(2009).
RN   [16]
RP   ENZYME REGULATION.
RX   PubMed=21036157; DOI=10.1016/j.bbrc.2010.10.101;
RA   Yao X., Balamurugan P., Arvey A., Leslie C., Zhang L.;
RT   "Heme controls the regulation of protein tyrosine kinases Jak2 and
RT   Src.";
RL   Biochem. Biophys. Res. Commun. 403:30-35(2010).
RN   [17]
RP   INTERACTION WITH HSP90AB1.
RX   PubMed=20353823; DOI=10.1016/j.cellsig.2010.03.012;
RA   Cheng M.B., Zhang Y., Zhong X., Sutter B., Cao C.Y., Chen X.S.,
RA   Cheng X.K., Zhang Y., Xiao L., Shen Y.F.;
RT   "Stat1 mediates an auto-regulation of hsp90beta gene in heat shock
RT   response.";
RL   Cell. Signal. 22:1206-1213(2010).
RN   [18]
RP   FUNCTION.
RX   PubMed=20098430; DOI=10.1038/nm.2079;
RA   Guilluy C., Bregeon J., Toumaniantz G., Rolli-Derkinderen M.,
RA   Retailleau K., Loufrani L., Henrion D., Scalbert E., Bril A.,
RA   Torres R.M., Offermanns S., Pacaud P., Loirand G.;
RT   "The Rho exchange factor Arhgef1 mediates the effects of angiotensin
RT   II on vascular tone and blood pressure.";
RL   Nat. Med. 16:183-190(2010).
RN   [19]
RP   FUNCTION IN PHOSPHORYLATION OF CDKN1B.
RX   PubMed=21423214; DOI=10.1038/onc.2011.68;
RA   Jakel H., Weinl C., Hengst L.;
RT   "Phosphorylation of p27Kip1 by JAK2 directly links cytokine receptor
RT   signaling to cell cycle control.";
RL   Oncogene 30:3502-3512(2011).
RN   [20]
RP   REVIEW ON FUNCTION.
RX   PubMed=16456223; DOI=10.1385/CBB:44:2:213;
RA   Wallace T.A., Sayeski P.P.;
RT   "Jak2 tyrosine kinase: a mediator of both housekeeping and ligand-
RT   dependent gene expression?";
RL   Cell Biochem. Biophys. 44:213-222(2006).
RN   [21]
RP   REVIEW ON FUNCTION.
RX   PubMed=19290934; DOI=10.1111/j.1600-065X.2008.00754.x;
RA   Ghoreschi K., Laurence A., O'Shea J.J.;
RT   "Janus kinases in immune cell signaling.";
RL   Immunol. Rev. 228:273-287(2009).
RN   [22]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-570, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [23]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 840-1132 IN COMPLEX WITH
RP   SYNTHETIC INHIBITOR, IDENTIFICATION BY MASS SPECTROMETRY, AND
RP   PHOSPHORYLATION AT TYR-1007 AND TYR-1008.
RX   PubMed=16174768; DOI=10.1182/blood-2005-06-2413;
RA   Lucet I.S., Fantino E., Styles M., Bamert R., Patel O.,
RA   Broughton S.E., Walter M., Burns C.J., Treutlein H., Wilks A.F.,
RA   Rossjohn J.;
RT   "The structural basis of Janus kinase 2 inhibition by a potent and
RT   specific pan-Janus kinase inhibitor.";
RL   Blood 107:176-183(2006).
RN   [24]
RP   VARIANT PV PHE-617.
RX   PubMed=15781101; DOI=10.1016/S0140-6736(05)71142-9;
RG   The cancer genome project;
RA   Baxter E.J., Scott L.M., Campbell P.J., East C., Fourouclas N.,
RA   Swanton S., Vassiliou G.S., Bench A.J., Boyd E.M., Curtin N.,
RA   Scott M.A., Erber W.N., Green A.R.;
RT   "Acquired mutation of the tyrosine kinase JAK2 in human
RT   myeloproliferative disorders.";
RL   Lancet 365:1054-1061(2005).
RN   [25]
RP   ERRATUM.
RG   The cancer genome project;
RA   Baxter E.J., Scott L.M., Campbell P.J., East C., Fourouclas N.,
RA   Swanton S., Vassiliou G.S., Bench A.J., Boyd E.M., Curtin N.,
RA   Scott M.A., Erber W.N., Green A.R.;
RL   Lancet 366:122-122(2005).
RN   [26]
RP   VARIANT THCYT3 PHE-617.
RX   PubMed=16325696; DOI=10.1016/S0140-6736(05)67785-9;
RG   The United Kingdom myeloproliferative disorders study group;
RG   The medical research council adult leukaemia working party;
RG   The Australasian leukaemia and lymphoma group;
RA   Campbell P.J., Scott L.M., Buck G., Wheatley K., East C.L.,
RA   Marsden J.T., Duffy A., Boyd E.M., Bench A.J., Scott M.A.,
RA   Vassiliou G.S., Milligan D.W., Smith S.R., Erber W.N., Bareford D.,
RA   Wilkins B.S., Reilly J.T., Harrison C.N., Green A.R.;
RT   "Definition of subtypes of essential thrombocythaemia and relation to
RT   polycythaemia vera based on JAK2 V617F mutation status: a prospective
RT   study.";
RL   Lancet 366:1945-1953(2005).
RN   [27]
RP   VARIANT PV PHE-617, AND CHARACTERIZATION OF VARIANT PV PHE-617.
RX   PubMed=15793561; DOI=10.1038/nature03546;
RA   James C., Ugo V., Le Couedic J.-P., Staerk J., Delhommeau F.,
RA   Lacout C., Garcon L., Raslova H., Berger R., Bennaceur-Griscelli A.,
RA   Villeval J.L., Constantinescu S.N., Casadevall N., Vainchenker W.;
RT   "A unique clonal JAK2 mutation leading to constitutive signalling
RT   causes polycythaemia vera.";
RL   Nature 434:1144-1148(2005).
RN   [28]
RP   VARIANT PV PHE-617.
RX   PubMed=15858187; DOI=10.1056/NEJMoa051113;
RA   Kralovics R., Passamonti F., Buser A.S., Teo S.-S., Tiedt R.,
RA   Passweg J.R., Tichelli A., Cazzola M., Skoda R.C.;
RT   "A gain-of-function mutation of JAK2 in myeloproliferative
RT   disorders.";
RL   N. Engl. J. Med. 352:1779-1790(2005).
RN   [29]
RP   ASSOCIATION OF VARIANT PHE-617 WITH SUSCEPTIBILITY BUDD-CHIARI
RP   SYNDROME.
RX   PubMed=16707754; DOI=10.1056/NEJMcpc069006;
RA   Chung R.T., Iafrate A.J., Amrein P.C., Sahani D.V., Misdraji J.;
RT   "Case records of the Massachusetts General Hospital. Case 15-2006: a
RT   46-year-old woman with sudden onset of abdominal distention.";
RL   N. Engl. J. Med. 354:2166-2175(2006).
RN   [30]
RP   VARIANTS AML ASN-607 AND PHE-617.
RX   PubMed=16247455; DOI=10.1038/sj.onc.1209163;
RA   Lee J.W., Kim Y.G., Soung Y.H., Han K.J., Kim S.Y., Rhim H.S.,
RA   Min W.S., Nam S.W., Park W.S., Lee J.Y., Yoo N.J., Lee S.H.;
RT   "The JAK2 V617F mutation in de novo acute myelogenous leukemias.";
RL   Oncogene 25:1434-1436(2006).
RN   [31]
RP   VARIANT PV PHE-617.
RX   PubMed=16603627; DOI=10.1073/pnas.0601462103;
RA   Jamieson C.H.M., Gotlib J., Durocher J.A., Chao M.P., Mariappan M.R.,
RA   Lay M., Jones C., Zehnder J.L., Lilleberg S.L., Weissman I.L.;
RT   "The JAK2 V617F mutation occurs in hematopoietic stem cells in
RT   polycythemia vera and predisposes toward erythroid differentiation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:6224-6229(2006).
RN   [32]
RP   VARIANTS MYELOPROLIFERATIVE DISORDER WITH ERYTHROCYTOSIS
RP   537-PHE--LYS-539 DELINS LEU; 538-GLN-LEU-539 AND LEU-539.
RX   PubMed=17267906; DOI=10.1056/NEJMoa065202;
RA   Scott L.M., Tong W., Levine R.L., Scott M.A., Beer P.A.,
RA   Stratton M.R., Futreal P.A., Erber W.N., McMullin M.F., Harrison C.N.,
RA   Warren A.J., Gilliland D.G., Lodish H.F., Green A.R.;
RT   "JAK2 exon 12 mutations in polycythemia vera and idiopathic
RT   erythrocytosis.";
RL   N. Engl. J. Med. 356:459-468(2007).
RN   [33]
RP   VARIANTS [LARGE SCALE ANALYSIS] ASP-127; GLN-191; ARG-346; GLU-377;
RP   VAL-393 AND HIS-1063.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [34]
RP   VARIANT THCYT3 ILE-617.
RX   PubMed=22397670; DOI=10.1056/NEJMc1200349;
RA   Mead A.J., Rugless M.J., Jacobsen S.E., Schuh A.;
RT   "Germline JAK2 mutation in a family with hereditary thrombocytosis.";
RL   N. Engl. J. Med. 366:967-969(2012).
CC   -!- FUNCTION: Non-receptor tyrosine kinase involved in various
CC       processes such as cell growth, development, differentiation or
CC       histone modifications. Mediates essential signaling events in both
CC       innate and adaptive immunity. In the cytoplasm, plays a pivotal
CC       role in signal transduction via its association with type I
CC       receptors such as growth hormone (GHR), prolactin (PRLR), leptin
CC       (LEPR), erythropoietin (EPOR), thrombopoietin (THPO); or type II
CC       receptors including IFN-alpha, IFN-beta, IFN-gamma and multiple
CC       interleukins (PubMed:7615558). Following ligand-binding to cell
CC       surface receptors, phosphorylates specific tyrosine residues on
CC       the cytoplasmic tails of the receptor, creating docking sites for
CC       STATs proteins (PubMed:9618263). Subsequently, phosphorylates the
CC       STATs proteins once they are recruited to the receptor.
CC       Phosphorylated STATs then form homodimer or heterodimers and
CC       translocate to the nucleus to activate gene transcription. For
CC       example, cell stimulation with erythropoietin (EPO) during
CC       erythropoiesis leads to JAK2 autophosphorylation, activation, and
CC       its association with erythropoietin receptor (EPOR) that becomes
CC       phosphorylated in its cytoplasmic domain. Then, STAT5 (STAT5A or
CC       STAT5B) is recruited, phosphorylated and activated by JAK2. Once
CC       activated, dimerized STAT5 translocates into the nucleus and
CC       promotes the transcription of several essential genes involved in
CC       the modulation of erythropoiesis. In addition, JAK2 mediates
CC       angiotensin-2-induced ARHGEF1 phosphorylation (PubMed:20098430).
CC       Plays a role in cell cycle by phosphorylating CDKN1B
CC       (PubMed:21423214). Cooperates with TEC through reciprocal
CC       phosphorylation to mediate cytokine-driven activation of FOS
CC       transcription. In the nucleus, plays a key role in chromatin by
CC       specifically mediating phosphorylation of 'Tyr-41' of histone H3
CC       (H3Y41ph), a specific tag that promotes exclusion of CBX5 (HP1
CC       alpha) from chromatin (PubMed:19783980).
CC       {ECO:0000269|PubMed:12023369, ECO:0000269|PubMed:19783980,
CC       ECO:0000269|PubMed:20098430, ECO:0000269|PubMed:21423214,
CC       ECO:0000269|PubMed:7615558, ECO:0000269|PubMed:9618263}.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate. {ECO:0000255|PROSITE-
CC       ProRule:PRU10028, ECO:0000269|PubMed:7615558,
CC       ECO:0000269|PubMed:9618263}.
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000305};
CC       Note=Mn(2+) was used in the in vitro kinase assay but Mg(2+) is
CC       likely to be the in vivo cofactor. {ECO:0000305|PubMed:7615558};
CC   -!- ENZYME REGULATION: Regulated by autophosphorylation, can both
CC       activate or decrease activity (By similarity). Heme regulates its
CC       activity by enhancing the phosphorylation on Tyr-1007 and Tyr-
CC       1008. {ECO:0000250, ECO:0000269|PubMed:21036157}.
CC   -!- SUBUNIT: Interacts with EPOR, LYN, SIRPA, SH2B1 and TEC (By
CC       similarity). Interacts with IL23R (PubMed:12023369). Interacts
CC       with SKB1 (PubMed:10531356). Interacts with STAM2
CC       (PubMed:10899310). Interacts with IFNGR2 (via intracellular
CC       domain) (PubMed:7673114, PubMed:7615558). Interacts with LEPR
CC       (Isoform B) (By similarity). Interacts with HSP90AB1; promotes
CC       functional activation in a heat shock-dependent manner
CC       (PubMed:20353823). {ECO:0000250|UniProtKB:Q62120,
CC       ECO:0000269|PubMed:10531356, ECO:0000269|PubMed:10899310,
CC       ECO:0000269|PubMed:12023369, ECO:0000269|PubMed:16174768,
CC       ECO:0000269|PubMed:20353823, ECO:0000269|PubMed:7615558,
CC       ECO:0000269|PubMed:7673114}.
CC   -!- INTERACTION:
CC       P32927:CSF2RB; NbExp=4; IntAct=EBI-518647, EBI-1809771;
CC       Q01344:IL5RA; NbExp=2; IntAct=EBI-518647, EBI-1759442;
CC       P40238:MPL; NbExp=6; IntAct=EBI-518647, EBI-6511486;
CC       P16333:NCK1; NbExp=2; IntAct=EBI-518647, EBI-389883;
CC       P18031:PTPN1; NbExp=5; IntAct=EBI-518647, EBI-968788;
CC   -!- SUBCELLULAR LOCATION: Endomembrane system {ECO:0000250};
CC       Peripheral membrane protein {ECO:0000250}. Cytoplasm
CC       {ECO:0000269|PubMed:19783980}. Nucleus
CC       {ECO:0000269|PubMed:19783980}.
CC   -!- TISSUE SPECIFICITY: Ubiquitously expressed throughout most
CC       tissues. {ECO:0000269|PubMed:16424865}.
CC   -!- DOMAIN: Possesses 2 protein kinase domains. The second one
CC       probably contains the catalytic domain, while the presence of
CC       slight differences suggest a different role for protein kinase 1
CC       (By similarity). {ECO:0000250}.
CC   -!- PTM: Autophosphorylated, leading to regulate its activity. Leptin
CC       promotes phosphorylation on tyrosine residues, including
CC       phosphorylation on Tyr-813 (By similarity). Autophosphorylation on
CC       Tyr-119 in response to EPO down-regulates its kinase activity (By
CC       similarity). Autophosphorylation on Tyr-868, Tyr-966 and Tyr-972
CC       in response to growth hormone (GH) are required for maximal kinase
CC       activity (By similarity). Also phosphorylated by TEC (By
CC       similarity). Phosphorylated on tyrosine residues in response to
CC       interferon gamma signaling (PubMed:7615558, PubMed:7673114).
CC       {ECO:0000250|UniProtKB:Q62120, ECO:0000269|PubMed:7615558,
CC       ECO:0000269|PubMed:7673114}.
CC   -!- DISEASE: Note=Chromosomal aberrations involving JAK2 are found in
CC       both chronic and acute forms of eosinophilic, lymphoblastic and
CC       myeloid leukemia. Translocation t(8;9)(p22;p24) with PCM1 links
CC       the protein kinase domain of JAK2 to the major portion of PCM1.
CC       Translocation t(9;12)(p24;p13) with ETV6.
CC   -!- DISEASE: Budd-Chiari syndrome (BDCHS) [MIM:600880]: A syndrome
CC       caused by obstruction of hepatic venous outflow involving either
CC       the hepatic veins or the terminal segment of the inferior vena
CC       cava. Obstructions are generally caused by thrombosis and lead to
CC       hepatic congestion and ischemic necrosis. Clinical manifestations
CC       observed in the majority of patients include hepatomegaly, right
CC       upper quadrant pain and abdominal ascites. Budd-Chiari syndrome is
CC       associated with a combination of disease states including primary
CC       myeloproliferative syndromes and thrombophilia due to factor V
CC       Leiden, protein C deficiency and antithrombin III deficiency.
CC       Budd-Chiari syndrome is a rare but typical complication in
CC       patients with polycythemia vera. {ECO:0000269|PubMed:16707754}.
CC       Note=Disease susceptibility is associated with variations
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Polycythemia vera (PV) [MIM:263300]: A myeloproliferative
CC       disorder characterized by abnormal proliferation of all
CC       hematopoietic bone marrow elements, erythroid hyperplasia, an
CC       absolute increase in total blood volume, but also by myeloid
CC       leukocytosis, thrombocytosis and splenomegaly.
CC       {ECO:0000269|PubMed:15781101, ECO:0000269|PubMed:15793561,
CC       ECO:0000269|PubMed:15858187, ECO:0000269|PubMed:16603627}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- DISEASE: Thrombocythemia 3 (THCYT3) [MIM:614521]: A
CC       myeloproliferative disorder characterized by excessive platelet
CC       production, resulting in increased numbers of circulating
CC       platelets. It can be associated with spontaneous hemorrhages and
CC       thrombotic episodes. {ECO:0000269|PubMed:16325696,
CC       ECO:0000269|PubMed:22397670}. Note=The disease may be caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Myelofibrosis (MYELOF) [MIM:254450]: A disorder
CC       characterized by replacement of the bone marrow by fibrous tissue,
CC       occurring in association with a myeloproliferative disorder.
CC       Clinical manifestations may include anemia, pallor, splenomegaly,
CC       hypermetabolic state, petechiae, ecchymosis, bleeding,
CC       lymphadenopathy, hepatomegaly, portal hypertension. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- DISEASE: Leukemia, acute myelogenous (AML) [MIM:601626]: A subtype
CC       of acute leukemia, a cancer of the white blood cells. AML is a
CC       malignant disease of bone marrow characterized by maturational
CC       arrest of hematopoietic precursors at an early stage of
CC       development. Clonal expansion of myeloid blasts occurs in bone
CC       marrow, blood, and other tissue. Myelogenous leukemias develop
CC       from changes in cells that normally produce neutrophils,
CC       basophils, eosinophils and monocytes.
CC       {ECO:0000269|PubMed:16247455}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. JAK subfamily. {ECO:0000255|PROSITE-
CC       ProRule:PRU00159}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/JAKID98.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF058925; AAC23982.1; -; mRNA.
DR   EMBL; AF001362; AAC23653.1; -; mRNA.
DR   EMBL; AF005216; AAB82092.1; -; mRNA.
DR   EMBL; AL161450; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   CCDS; CCDS6457.1; -.
DR   PIR; JW0091; JW0091.
DR   RefSeq; NP_001309123.1; NM_001322194.1.
DR   RefSeq; NP_001309124.1; NM_001322195.1.
DR   RefSeq; NP_001309125.1; NM_001322196.1.
DR   RefSeq; NP_001309133.1; NM_001322204.1.
DR   RefSeq; NP_004963.1; NM_004972.3.
DR   UniGene; Hs.656213; -.
DR   PDB; 2B7A; X-ray; 2.00 A; A/B=840-1132.
DR   PDB; 2W1I; X-ray; 2.60 A; A/B=835-1132.
DR   PDB; 2XA4; X-ray; 2.04 A; A/B=835-1132.
DR   PDB; 3E62; X-ray; 1.92 A; A=839-1131.
DR   PDB; 3E63; X-ray; 1.90 A; A=839-1131.
DR   PDB; 3E64; X-ray; 1.80 A; A=839-1131.
DR   PDB; 3FUP; X-ray; 2.40 A; A/B=840-1132.
DR   PDB; 3IO7; X-ray; 2.60 A; A=842-1132.
DR   PDB; 3IOK; X-ray; 2.10 A; A=842-1132.
DR   PDB; 3JY9; X-ray; 2.10 A; A=842-1130.
DR   PDB; 3KCK; X-ray; 2.20 A; A=842-1132.
DR   PDB; 3KRR; X-ray; 1.80 A; A=840-1132.
DR   PDB; 3LPB; X-ray; 2.00 A; A/B=840-1132.
DR   PDB; 3Q32; X-ray; 2.50 A; A/B=839-1132.
DR   PDB; 3RVG; X-ray; 2.50 A; A=835-1132.
DR   PDB; 3TJC; X-ray; 2.40 A; A/B=837-1132.
DR   PDB; 3TJD; X-ray; 2.90 A; A/B=837-1132.
DR   PDB; 3UGC; X-ray; 1.34 A; A=840-1132.
DR   PDB; 3ZMM; X-ray; 2.51 A; A/B=835-1132.
DR   PDB; 4AQC; X-ray; 1.90 A; A/B=835-1132.
DR   PDB; 4BBE; X-ray; 1.90 A; A/B/C/D=839-1132.
DR   PDB; 4BBF; X-ray; 2.00 A; A/B/C/D=839-1132.
DR   PDB; 4C61; X-ray; 2.45 A; A/B=835-1132.
DR   PDB; 4C62; X-ray; 2.75 A; A/B=835-1132.
DR   PDB; 4D0W; X-ray; 1.77 A; A=835-1132.
DR   PDB; 4D0X; X-ray; 1.82 A; A=835-1132.
DR   PDB; 4D1S; X-ray; 1.66 A; A=835-1132.
DR   PDB; 4E4M; X-ray; 2.25 A; A/B/D/E=833-1132.
DR   PDB; 4E6D; X-ray; 2.22 A; A/B=835-1132.
DR   PDB; 4E6Q; X-ray; 1.95 A; A/B=835-1132.
DR   PDB; 4F08; X-ray; 2.82 A; A/B=833-1132.
DR   PDB; 4F09; X-ray; 2.40 A; A=833-1132.
DR   PDB; 4FVP; X-ray; 2.01 A; A=536-812.
DR   PDB; 4FVQ; X-ray; 1.75 A; A=536-812.
DR   PDB; 4FVR; X-ray; 2.00 A; A=536-812.
DR   PDB; 4GFM; X-ray; 2.30 A; A=833-1132.
DR   PDB; 4GMY; X-ray; 2.40 A; A=833-1132.
DR   PDB; 4HGE; X-ray; 2.30 A; A/B=833-1132.
DR   PDB; 4IVA; X-ray; 1.50 A; A=833-1132.
DR   PDB; 4JI9; X-ray; 2.40 A; A/B=833-1132.
DR   PDB; 4JIA; X-ray; 1.85 A; A=833-1132.
DR   PDB; 4P7E; X-ray; 2.40 A; A/B=840-1132.
DR   PDB; 4YTC; X-ray; 2.16 A; A=842-1132.
DR   PDB; 4YTF; X-ray; 1.78 A; A=842-1132.
DR   PDB; 4YTH; X-ray; 2.04 A; A=842-1132.
DR   PDB; 4YTI; X-ray; 2.52 A; A=842-1132.
DR   PDB; 4Z32; X-ray; 3.04 A; A/B/C/D/E/F/G/H=31-516.
DR   PDB; 4ZIM; X-ray; 2.65 A; A/B=839-1132.
DR   PDB; 5AEP; X-ray; 1.95 A; A=835-1132.
DR   PDB; 5CF4; X-ray; 2.38 A; A/B=839-1132.
DR   PDB; 5CF5; X-ray; 2.45 A; A/B=839-1132.
DR   PDB; 5CF6; X-ray; 2.50 A; A/B=839-1132.
DR   PDB; 5CF8; X-ray; 1.80 A; A/B=839-1132.
DR   PDB; 5HEZ; X-ray; 2.66 A; A/B/C/D=833-1132.
DR   PDB; 5I4N; X-ray; 1.54 A; A=535-812.
DR   PDB; 5L3A; X-ray; 1.98 A; A=840-1132.
DR   PDB; 5TQ3; X-ray; 2.69 A; A/B=837-1132.
DR   PDB; 5TQ4; X-ray; 2.30 A; A=837-1132.
DR   PDB; 5TQ5; X-ray; 2.30 A; A=837-1132.
DR   PDB; 5TQ6; X-ray; 2.06 A; A/B=837-1132.
DR   PDB; 5TQ7; X-ray; 2.10 A; A/B=837-1132.
DR   PDB; 5TQ8; X-ray; 1.59 A; A=837-1132.
DR   PDBsum; 2B7A; -.
DR   PDBsum; 2W1I; -.
DR   PDBsum; 2XA4; -.
DR   PDBsum; 3E62; -.
DR   PDBsum; 3E63; -.
DR   PDBsum; 3E64; -.
DR   PDBsum; 3FUP; -.
DR   PDBsum; 3IO7; -.
DR   PDBsum; 3IOK; -.
DR   PDBsum; 3JY9; -.
DR   PDBsum; 3KCK; -.
DR   PDBsum; 3KRR; -.
DR   PDBsum; 3LPB; -.
DR   PDBsum; 3Q32; -.
DR   PDBsum; 3RVG; -.
DR   PDBsum; 3TJC; -.
DR   PDBsum; 3TJD; -.
DR   PDBsum; 3UGC; -.
DR   PDBsum; 3ZMM; -.
DR   PDBsum; 4AQC; -.
DR   PDBsum; 4BBE; -.
DR   PDBsum; 4BBF; -.
DR   PDBsum; 4C61; -.
DR   PDBsum; 4C62; -.
DR   PDBsum; 4D0W; -.
DR   PDBsum; 4D0X; -.
DR   PDBsum; 4D1S; -.
DR   PDBsum; 4E4M; -.
DR   PDBsum; 4E6D; -.
DR   PDBsum; 4E6Q; -.
DR   PDBsum; 4F08; -.
DR   PDBsum; 4F09; -.
DR   PDBsum; 4FVP; -.
DR   PDBsum; 4FVQ; -.
DR   PDBsum; 4FVR; -.
DR   PDBsum; 4GFM; -.
DR   PDBsum; 4GMY; -.
DR   PDBsum; 4HGE; -.
DR   PDBsum; 4IVA; -.
DR   PDBsum; 4JI9; -.
DR   PDBsum; 4JIA; -.
DR   PDBsum; 4P7E; -.
DR   PDBsum; 4YTC; -.
DR   PDBsum; 4YTF; -.
DR   PDBsum; 4YTH; -.
DR   PDBsum; 4YTI; -.
DR   PDBsum; 4Z32; -.
DR   PDBsum; 4ZIM; -.
DR   PDBsum; 5AEP; -.
DR   PDBsum; 5CF4; -.
DR   PDBsum; 5CF5; -.
DR   PDBsum; 5CF6; -.
DR   PDBsum; 5CF8; -.
DR   PDBsum; 5HEZ; -.
DR   PDBsum; 5I4N; -.
DR   PDBsum; 5L3A; -.
DR   PDBsum; 5TQ3; -.
DR   PDBsum; 5TQ4; -.
DR   PDBsum; 5TQ5; -.
DR   PDBsum; 5TQ6; -.
DR   PDBsum; 5TQ7; -.
DR   PDBsum; 5TQ8; -.
DR   ProteinModelPortal; O60674; -.
DR   SMR; O60674; -.
DR   BioGrid; 109920; 93.
DR   DIP; DIP-33880N; -.
DR   IntAct; O60674; 31.
DR   MINT; MINT-158048; -.
DR   STRING; 9606.ENSP00000371067; -.
DR   BindingDB; O60674; -.
DR   ChEMBL; CHEMBL2971; -.
DR   DrugBank; DB07162; 4-(3-amino-1H-indazol-5-yl)-N-tert-butylbenzenesulfonamide.
DR   DrugBank; DB08067; 4-[(2-{4-[(CYCLOPROPYLCARBAMOYL)AMINO]-1H-PYRAZOL-3-YL}-1H-BENZIMIDAZOL-6-YL)METHYL]MORPHOLIN-4-IUM.
DR   DrugBank; DB07161; 5-phenyl-1H-indazol-3-amine.
DR   DrugBank; DB08877; Ruxolitinib.
DR   DrugBank; DB08895; Tofacitinib.
DR   DrugBank; DB05243; XL019.
DR   GuidetoPHARMACOLOGY; 2048; -.
DR   iPTMnet; O60674; -.
DR   PhosphoSitePlus; O60674; -.
DR   BioMuta; JAK2; -.
DR   EPD; O60674; -.
DR   MaxQB; O60674; -.
DR   PaxDb; O60674; -.
DR   PeptideAtlas; O60674; -.
DR   PRIDE; O60674; -.
DR   DNASU; 3717; -.
DR   Ensembl; ENST00000381652; ENSP00000371067; ENSG00000096968.
DR   GeneID; 3717; -.
DR   KEGG; hsa:3717; -.
DR   UCSC; uc003ziw.3; human.
DR   CTD; 3717; -.
DR   DisGeNET; 3717; -.
DR   GeneCards; JAK2; -.
DR   HGNC; HGNC:6192; JAK2.
DR   HPA; CAB013089; -.
DR   HPA; HPA040820; -.
DR   HPA; HPA043870; -.
DR   MalaCards; JAK2; -.
DR   MIM; 147796; gene.
DR   MIM; 254450; phenotype.
DR   MIM; 263300; phenotype.
DR   MIM; 600880; phenotype.
DR   MIM; 601626; phenotype.
DR   MIM; 614521; phenotype.
DR   neXtProt; NX_O60674; -.
DR   OpenTargets; ENSG00000096968; -.
DR   Orphanet; 131; Budd-Chiari syndrome.
DR   Orphanet; 3318; Essential thrombocythemia.
DR   Orphanet; 71493; Familial thrombocytosis.
DR   Orphanet; 824; Myelofibrosis with myeloid metaplasia.
DR   Orphanet; 729; Polycythemia vera.
DR   PharmGKB; PA29989; -.
DR   eggNOG; KOG0197; Eukaryota.
DR   eggNOG; COG0515; LUCA.
DR   GeneTree; ENSGT00760000118799; -.
DR   HOGENOM; HOG000049158; -.
DR   HOVERGEN; HBG006195; -.
DR   InParanoid; O60674; -.
DR   KO; K04447; -.
DR   OMA; CHGPISM; -.
DR   OrthoDB; EOG091G01IS; -.
DR   PhylomeDB; O60674; -.
DR   TreeFam; TF327041; -.
DR   BRENDA; 2.7.10.2; 2681.
DR   Reactome; R-HSA-1059683; Interleukin-6 signaling.
DR   Reactome; R-HSA-110056; MAPK3 (ERK1) activation.
DR   Reactome; R-HSA-112411; MAPK1 (ERK2) activation.
DR   Reactome; R-HSA-114604; GPVI-mediated activation cascade.
DR   Reactome; R-HSA-1170546; Prolactin receptor signaling.
DR   Reactome; R-HSA-1433557; Signaling by SCF-KIT.
DR   Reactome; R-HSA-2586552; Signaling by Leptin.
DR   Reactome; R-HSA-3214858; RMTs methylate histone arginines.
DR   Reactome; R-HSA-392451; G beta:gamma signalling through PI3Kgamma.
DR   Reactome; R-HSA-512988; Interleukin-3, 5 and GM-CSF signaling.
DR   Reactome; R-HSA-5673000; RAF activation.
DR   Reactome; R-HSA-5673001; RAF/MAP kinase cascade.
DR   Reactome; R-HSA-6785807; Interleukin-4 and 13 signaling.
DR   Reactome; R-HSA-6788467; IL-6-type cytokine receptor ligand interactions.
DR   Reactome; R-HSA-6802946; Signaling by moderate kinase activity BRAF mutants.
DR   Reactome; R-HSA-6802949; Signaling by RAS mutants.
DR   Reactome; R-HSA-6802952; Signaling by BRAF and RAF fusions.
DR   Reactome; R-HSA-6802955; Paradoxical activation of RAF signaling by kinase inactive BRAF.
DR   Reactome; R-HSA-877300; Interferon gamma signaling.
DR   Reactome; R-HSA-877312; Regulation of IFNG signaling.
DR   Reactome; R-HSA-912526; Interleukin receptor SHC signaling.
DR   Reactome; R-HSA-982772; Growth hormone receptor signaling.
DR   Reactome; R-HSA-983231; Factors involved in megakaryocyte development and platelet production.
DR   SignaLink; O60674; -.
DR   SIGNOR; O60674; -.
DR   ChiTaRS; JAK2; human.
DR   EvolutionaryTrace; O60674; -.
DR   GeneWiki; Janus_kinase_2; -.
DR   GenomeRNAi; 3717; -.
DR   PRO; PR:O60674; -.
DR   Proteomes; UP000005640; Chromosome 9.
DR   Bgee; ENSG00000096968; -.
DR   CleanEx; HS_JAK2; -.
DR   ExpressionAtlas; O60674; baseline and differential.
DR   Genevisible; O60674; HS.
DR   GO; GO:0005901; C:caveola; ISS:BHF-UCL.
DR   GO; GO:0005737; C:cytoplasm; IDA:BHF-UCL.
DR   GO; GO:0005856; C:cytoskeleton; IEA:InterPro.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0031904; C:endosome lumen; TAS:Reactome.
DR   GO; GO:0031234; C:extrinsic component of cytoplasmic side of plasma membrane; IBA:GO_Central.
DR   GO; GO:0005925; C:focal adhesion; IDA:HPA.
DR   GO; GO:0045121; C:membrane raft; ISS:BHF-UCL.
DR   GO; GO:0016363; C:nuclear matrix; IEA:Ensembl.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:HPA.
DR   GO; GO:0033130; F:acetylcholine receptor binding; IEA:Ensembl.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0005131; F:growth hormone receptor binding; ISS:BHF-UCL.
DR   GO; GO:0020037; F:heme binding; IDA:UniProtKB.
DR   GO; GO:0042393; F:histone binding; IDA:UniProtKB.
DR   GO; GO:0035401; F:histone kinase activity (H3-Y41 specific); IDA:UniProtKB.
DR   GO; GO:0043560; F:insulin receptor substrate binding; IEA:Ensembl.
DR   GO; GO:0005143; F:interleukin-12 receptor binding; ISS:BHF-UCL.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0004715; F:non-membrane spanning protein tyrosine kinase activity; TAS:Reactome.
DR   GO; GO:0051428; F:peptide hormone receptor binding; IEA:Ensembl.
DR   GO; GO:0043548; F:phosphatidylinositol 3-kinase binding; IEA:Ensembl.
DR   GO; GO:0008022; F:protein C-terminus binding; IEA:Ensembl.
DR   GO; GO:0004672; F:protein kinase activity; NAS:ProtInc.
DR   GO; GO:0019901; F:protein kinase binding; IDA:BHF-UCL.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; IDA:CACAO.
DR   GO; GO:0005088; F:Ras guanyl-nucleotide exchange factor activity; TAS:Reactome.
DR   GO; GO:0005102; F:receptor binding; IPI:UniProtKB.
DR   GO; GO:0042169; F:SH2 domain binding; IPI:UniProtKB.
DR   GO; GO:0031702; F:type 1 angiotensin receptor binding; IEA:Ensembl.
DR   GO; GO:0030041; P:actin filament polymerization; NAS:BHF-UCL.
DR   GO; GO:0006919; P:activation of cysteine-type endopeptidase activity involved in apoptotic process; ISS:BHF-UCL.
DR   GO; GO:0097296; P:activation of cysteine-type endopeptidase activity involved in apoptotic signaling pathway; ISS:BHF-UCL.
DR   GO; GO:0042977; P:activation of JAK2 kinase activity; ISS:UniProtKB.
DR   GO; GO:0000186; P:activation of MAPKK activity; IEA:Ensembl.
DR   GO; GO:0002250; P:adaptive immune response; IEA:UniProtKB-KW.
DR   GO; GO:0006915; P:apoptotic process; ISS:BHF-UCL.
DR   GO; GO:0031103; P:axon regeneration; IEA:Ensembl.
DR   GO; GO:0007596; P:blood coagulation; TAS:Reactome.
DR   GO; GO:0030154; P:cell differentiation; ISS:BHF-UCL.
DR   GO; GO:0016477; P:cell migration; IBA:GO_Central.
DR   GO; GO:0019221; P:cytokine-mediated signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0007167; P:enzyme linked receptor protein signaling pathway; ISS:BHF-UCL.
DR   GO; GO:0030218; P:erythrocyte differentiation; ISS:UniProtKB.
DR   GO; GO:0097191; P:extrinsic apoptotic signaling pathway; ISS:BHF-UCL.
DR   GO; GO:0007186; P:G-protein coupled receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0060396; P:growth hormone receptor signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0035409; P:histone H3-Y41 phosphorylation; IDA:UniProtKB.
DR   GO; GO:0045087; P:innate immune response; IBA:GO_Central.
DR   GO; GO:0060333; P:interferon-gamma-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0035722; P:interleukin-12-mediated signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0035556; P:intracellular signal transduction; ISS:BHF-UCL.
DR   GO; GO:0008631; P:intrinsic apoptotic signaling pathway in response to oxidative stress; IEA:Ensembl.
DR   GO; GO:0007259; P:JAK-STAT cascade; TAS:ProtInc.
DR   GO; GO:0060397; P:JAK-STAT cascade involved in growth hormone signaling pathway; ISS:UniProtKB.
DR   GO; GO:0061180; P:mammary gland epithelium development; ISS:BHF-UCL.
DR   GO; GO:0000165; P:MAPK cascade; TAS:Reactome.
DR   GO; GO:0007498; P:mesoderm development; TAS:ProtInc.
DR   GO; GO:0031959; P:mineralocorticoid receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0006928; P:movement of cell or subcellular component; TAS:ProtInc.
DR   GO; GO:0010667; P:negative regulation of cardiac muscle cell apoptotic process; IEA:Ensembl.
DR   GO; GO:0008285; P:negative regulation of cell proliferation; ISS:BHF-UCL.
DR   GO; GO:0022408; P:negative regulation of cell-cell adhesion; IEA:Ensembl.
DR   GO; GO:0043392; P:negative regulation of DNA binding; ISS:BHF-UCL.
DR   GO; GO:0045822; P:negative regulation of heart contraction; IEA:Ensembl.
DR   GO; GO:0043524; P:negative regulation of neuron apoptotic process; IEA:Ensembl.
DR   GO; GO:0038083; P:peptidyl-tyrosine autophosphorylation; IBA:GO_Central.
DR   GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; ISS:BHF-UCL.
DR   GO; GO:0048008; P:platelet-derived growth factor receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0050867; P:positive regulation of cell activation; IEA:Ensembl.
DR   GO; GO:0045597; P:positive regulation of cell differentiation; IEA:Ensembl.
DR   GO; GO:0030335; P:positive regulation of cell migration; IEA:Ensembl.
DR   GO; GO:0010811; P:positive regulation of cell-substrate adhesion; IDA:BHF-UCL.
DR   GO; GO:0007204; P:positive regulation of cytosolic calcium ion concentration; IEA:Ensembl.
DR   GO; GO:0043388; P:positive regulation of DNA binding; IEA:Ensembl.
DR   GO; GO:1904037; P:positive regulation of epithelial cell apoptotic process; IEA:Ensembl.
DR   GO; GO:1902728; P:positive regulation of growth factor dependent skeletal muscle satellite cell proliferation; IEA:Ensembl.
DR   GO; GO:0060399; P:positive regulation of growth hormone receptor signaling pathway; ISS:BHF-UCL.
DR   GO; GO:0050729; P:positive regulation of inflammatory response; IEA:Ensembl.
DR   GO; GO:0032024; P:positive regulation of insulin secretion; IEA:Ensembl.
DR   GO; GO:0032731; P:positive regulation of interleukin-1 beta production; IEA:Ensembl.
DR   GO; GO:0045429; P:positive regulation of nitric oxide biosynthetic process; IEA:Ensembl.
DR   GO; GO:0051770; P:positive regulation of nitric-oxide synthase biosynthetic process; ISS:BHF-UCL.
DR   GO; GO:0050731; P:positive regulation of peptidyl-tyrosine phosphorylation; ISS:BHF-UCL.
DR   GO; GO:0014068; P:positive regulation of phosphatidylinositol 3-kinase signaling; ISS:BHF-UCL.
DR   GO; GO:0032516; P:positive regulation of phosphoprotein phosphatase activity; IEA:Ensembl.
DR   GO; GO:0033160; P:positive regulation of protein import into nucleus, translocation; IEA:Ensembl.
DR   GO; GO:0051091; P:positive regulation of sequence-specific DNA binding transcription factor activity; IEA:Ensembl.
DR   GO; GO:0032760; P:positive regulation of tumor necrosis factor production; ISS:BHF-UCL.
DR   GO; GO:0042517; P:positive regulation of tyrosine phosphorylation of Stat3 protein; ISS:UniProtKB.
DR   GO; GO:0042523; P:positive regulation of tyrosine phosphorylation of Stat5 protein; ISS:BHF-UCL.
DR   GO; GO:1904707; P:positive regulation of vascular smooth muscle cell proliferation; IEA:Ensembl.
DR   GO; GO:0046777; P:protein autophosphorylation; ISS:UniProtKB.
DR   GO; GO:0006468; P:protein phosphorylation; TAS:ProtInc.
DR   GO; GO:0042981; P:regulation of apoptotic process; IBA:GO_Central.
DR   GO; GO:0042127; P:regulation of cell proliferation; IBA:GO_Central.
DR   GO; GO:0050727; P:regulation of inflammatory response; IDA:BHF-UCL.
DR   GO; GO:0060334; P:regulation of interferon-gamma-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0046677; P:response to antibiotic; IDA:MGI.
DR   GO; GO:0033194; P:response to hydroperoxide; IEA:Ensembl.
DR   GO; GO:0070671; P:response to interleukin-12; IDA:BHF-UCL.
DR   GO; GO:0032496; P:response to lipopolysaccharide; ISS:BHF-UCL.
DR   GO; GO:0034612; P:response to tumor necrosis factor; IDA:BHF-UCL.
DR   GO; GO:0007165; P:signal transduction; ISS:UniProtKB.
DR   GO; GO:0007262; P:STAT protein import into nucleus; ISS:BHF-UCL.
DR   GO; GO:0033209; P:tumor necrosis factor-mediated signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0007260; P:tyrosine phosphorylation of STAT protein; ISS:BHF-UCL.
DR   GO; GO:0042508; P:tyrosine phosphorylation of Stat1 protein; IEA:Ensembl.
DR   GO; GO:0042503; P:tyrosine phosphorylation of Stat3 protein; IEA:Ensembl.
DR   GO; GO:0042506; P:tyrosine phosphorylation of Stat5 protein; IEA:Ensembl.
DR   Gene3D; 1.20.80.10; -; 1.
DR   Gene3D; 3.30.505.10; -; 1.
DR   InterPro; IPR019749; Band_41_domain.
DR   InterPro; IPR014352; FERM/acyl-CoA-bd_prot_3-hlx.
DR   InterPro; IPR019748; FERM_central.
DR   InterPro; IPR000299; FERM_domain.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR011993; PH_dom-like.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR000980; SH2.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   InterPro; IPR016251; Tyr_kinase_non-rcpt_Jak/Tyk2.
DR   InterPro; IPR020693; Tyr_kinase_non-rcpt_Jak2.
DR   Pfam; PF07714; Pkinase_Tyr; 2.
DR   Pfam; PF00017; SH2; 1.
DR   PIRSF; PIRSF000636; TyrPK_Jak; 1.
DR   PRINTS; PR01823; JANUSKINASE.
DR   PRINTS; PR01825; JANUSKINASE2.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00295; B41; 1.
DR   SMART; SM00252; SH2; 1.
DR   SMART; SM00219; TyrKc; 2.
DR   SUPFAM; SSF47031; SSF47031; 1.
DR   SUPFAM; SSF50729; SSF50729; 1.
DR   SUPFAM; SSF55550; SSF55550; 2.
DR   SUPFAM; SSF56112; SSF56112; 2.
DR   PROSITE; PS50057; FERM_3; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 2.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS50001; SH2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Adaptive immunity; ATP-binding; Chromatin regulator;
KW   Chromosomal rearrangement; Complete proteome; Cytoplasm;
KW   Disease mutation; Immunity; Innate immunity; Kinase; Magnesium;
KW   Membrane; Metal-binding; Nucleotide-binding; Nucleus; Phosphoprotein;
KW   Polymorphism; Proto-oncogene; Reference proteome; Repeat; SH2 domain;
KW   Transferase; Tyrosine-protein kinase.
FT   CHAIN         1   1132       Tyrosine-protein kinase JAK2.
FT                                /FTId=PRO_0000088112.
FT   DOMAIN       37    380       FERM. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00084}.
FT   DOMAIN      401    482       SH2; atypical. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00191}.
FT   DOMAIN      545    809       Protein kinase 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   DOMAIN      849   1124       Protein kinase 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     855    863       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   REGION        1    239       Interaction with
FT                                cytokine/interferon/growth hormone
FT                                receptors. {ECO:0000250}.
FT   ACT_SITE    976    976       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10028}.
FT   BINDING     882    882       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   SITE        352    353       Breakpoint for translocation to form
FT                                PCM1-JAK2 fusion protein.
FT   SITE        442    443       Breakpoint for translocation to form
FT                                PCM1-JAK2 fusion protein.
FT   SITE        450    451       Breakpoint for translocation to form
FT                                PCM1-JAK2 fusion protein.
FT   SITE        504    505       Breakpoint for translocation to form
FT                                PCM1-JAK2 fusion protein.
FT   SITE        710    711       Breakpoint for translocation to form
FT                                PCM1-JAK2 fusion protein.
FT   MOD_RES     119    119       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   MOD_RES     372    372       Phosphotyrosine.
FT                                {ECO:0000250|UniProtKB:Q62120}.
FT   MOD_RES     373    373       Phosphotyrosine.
FT                                {ECO:0000250|UniProtKB:Q62120}.
FT   MOD_RES     523    523       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q62120}.
FT   MOD_RES     570    570       Phosphotyrosine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     813    813       Phosphotyrosine.
FT                                {ECO:0000250|UniProtKB:Q62120}.
FT   MOD_RES     868    868       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   MOD_RES     966    966       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   MOD_RES     972    972       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   MOD_RES    1007   1007       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:16174768}.
FT   MOD_RES    1008   1008       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000305|PubMed:16174768}.
FT   VARIANT     127    127       G -> D (in dbSNP:rs56118985).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041716.
FT   VARIANT     191    191       K -> Q (in an ovarian serous carcinoma
FT                                sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041717.
FT   VARIANT     346    346       K -> R (in dbSNP:rs55667734).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041718.
FT   VARIANT     377    377       A -> E (in dbSNP:rs55953208).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041719.
FT   VARIANT     393    393       L -> V (in dbSNP:rs2230723).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041720.
FT   VARIANT     537    539       FHK -> L (in myeloproliferative disorder
FT                                with erythrocytosis).
FT                                {ECO:0000269|PubMed:17267906}.
FT                                /FTId=VAR_032693.
FT   VARIANT     538    539       HK -> QL (in myeloproliferative disorder
FT                                with erythrocytosis).
FT                                /FTId=VAR_032694.
FT   VARIANT     539    539       K -> L (in myeloproliferative disorder
FT                                with erythrocytosis; requires 2
FT                                nucleotide substitutions;
FT                                dbSNP:rs121912473).
FT                                {ECO:0000269|PubMed:17267906}.
FT                                /FTId=VAR_032695.
FT   VARIANT     584    584       D -> E (in dbSNP:rs17490221).
FT                                /FTId=VAR_043129.
FT   VARIANT     607    607       K -> N (in AML; dbSNP:rs121912472).
FT                                {ECO:0000269|PubMed:16247455}.
FT                                /FTId=VAR_032696.
FT   VARIANT     617    617       V -> F (in PV, THCYT3 and AML; associated
FT                                with susceptibility to Budd-Chiari
FT                                syndrome; somatic mutation in a high
FT                                percentage of patients with essential
FT                                thrombocythemia or myelofibrosis; leads
FT                                to constitutive tyrosine phosphorylation
FT                                activity that promotes cytokine
FT                                hypersensitivity; dbSNP:rs77375493).
FT                                {ECO:0000269|PubMed:15781101,
FT                                ECO:0000269|PubMed:15793561,
FT                                ECO:0000269|PubMed:15858187,
FT                                ECO:0000269|PubMed:16247455,
FT                                ECO:0000269|PubMed:16325696,
FT                                ECO:0000269|PubMed:16603627}.
FT                                /FTId=VAR_032697.
FT   VARIANT     617    617       V -> I (in THCYT3; dbSNP:rs77375493).
FT                                {ECO:0000269|PubMed:22397670}.
FT                                /FTId=VAR_067534.
FT   VARIANT    1063   1063       R -> H (in dbSNP:rs41316003).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041721.
FT   CONFLICT    321    321       P -> S (in Ref. 1; AAC23982).
FT                                {ECO:0000305}.
FT   CONFLICT   1126   1126       I -> V (in Ref. 2; AAC23653).
FT                                {ECO:0000305}.
FT   STRAND       38     45       {ECO:0000244|PDB:4Z32}.
FT   TURN         47     49       {ECO:0000244|PDB:4Z32}.
FT   STRAND       53     57       {ECO:0000244|PDB:4Z32}.
FT   STRAND       59     63       {ECO:0000244|PDB:4Z32}.
FT   HELIX        64     75       {ECO:0000244|PDB:4Z32}.
FT   HELIX        79     82       {ECO:0000244|PDB:4Z32}.
FT   STRAND       85     89       {ECO:0000244|PDB:4Z32}.
FT   TURN         90     92       {ECO:0000244|PDB:4Z32}.
FT   STRAND      101    104       {ECO:0000244|PDB:4Z32}.
FT   STRAND      109    116       {ECO:0000244|PDB:4Z32}.
FT   TURN        121    124       {ECO:0000244|PDB:4Z32}.
FT   STRAND      131    133       {ECO:0000244|PDB:4Z32}.
FT   TURN        136    139       {ECO:0000244|PDB:4Z32}.
FT   HELIX       147    162       {ECO:0000244|PDB:4Z32}.
FT   HELIX       172    192       {ECO:0000244|PDB:4Z32}.
FT   HELIX       197    201       {ECO:0000244|PDB:4Z32}.
FT   HELIX       206    209       {ECO:0000244|PDB:4Z32}.
FT   HELIX       212    219       {ECO:0000244|PDB:4Z32}.
FT   HELIX       223    239       {ECO:0000244|PDB:4Z32}.
FT   HELIX       247    261       {ECO:0000244|PDB:4Z32}.
FT   HELIX       263    265       {ECO:0000244|PDB:4Z32}.
FT   STRAND      268    271       {ECO:0000244|PDB:4Z32}.
FT   STRAND      286    291       {ECO:0000244|PDB:4Z32}.
FT   TURN        292    294       {ECO:0000244|PDB:4Z32}.
FT   STRAND      295    300       {ECO:0000244|PDB:4Z32}.
FT   STRAND      315    318       {ECO:0000244|PDB:4Z32}.
FT   HELIX       320    322       {ECO:0000244|PDB:4Z32}.
FT   STRAND      323    329       {ECO:0000244|PDB:4Z32}.
FT   STRAND      340    349       {ECO:0000244|PDB:4Z32}.
FT   STRAND      351    357       {ECO:0000244|PDB:4Z32}.
FT   HELIX       359    376       {ECO:0000244|PDB:4Z32}.
FT   TURN        385    387       {ECO:0000244|PDB:4Z32}.
FT   HELIX       390    397       {ECO:0000244|PDB:4Z32}.
FT   HELIX       406    415       {ECO:0000244|PDB:4Z32}.
FT   STRAND      423    427       {ECO:0000244|PDB:4Z32}.
FT   STRAND      432    443       {ECO:0000244|PDB:4Z32}.
FT   STRAND      446    455       {ECO:0000244|PDB:4Z32}.
FT   HELIX       474    481       {ECO:0000244|PDB:4Z32}.
FT   STRAND      485    488       {ECO:0000244|PDB:4Z32}.
FT   STRAND      491    495       {ECO:0000244|PDB:4Z32}.
FT   STRAND      510    513       {ECO:0000244|PDB:4Z32}.
FT   HELIX       542    544       {ECO:0000244|PDB:5I4N}.
FT   STRAND      545    554       {ECO:0000244|PDB:5I4N}.
FT   STRAND      557    567       {ECO:0000244|PDB:5I4N}.
FT   HELIX       569    571       {ECO:0000244|PDB:5I4N}.
FT   STRAND      573    584       {ECO:0000244|PDB:5I4N}.
FT   HELIX       588    602       {ECO:0000244|PDB:5I4N}.
FT   STRAND      612    616       {ECO:0000244|PDB:5I4N}.
FT   STRAND      618    627       {ECO:0000244|PDB:5I4N}.
FT   HELIX       634    640       {ECO:0000244|PDB:5I4N}.
FT   TURN        641    643       {ECO:0000244|PDB:5I4N}.
FT   HELIX       647    666       {ECO:0000244|PDB:5I4N}.
FT   HELIX       676    678       {ECO:0000244|PDB:5I4N}.
FT   STRAND      679    683       {ECO:0000244|PDB:5I4N}.
FT   TURN        687    690       {ECO:0000244|PDB:5I4N}.
FT   STRAND      694    697       {ECO:0000244|PDB:5I4N}.
FT   TURN        704    706       {ECO:0000244|PDB:5I4N}.
FT   HELIX       709    714       {ECO:0000244|PDB:5I4N}.
FT   TURN        715    718       {ECO:0000244|PDB:5I4N}.
FT   HELIX       721    725       {ECO:0000244|PDB:5I4N}.
FT   HELIX       727    729       {ECO:0000244|PDB:5I4N}.
FT   HELIX       732    746       {ECO:0000244|PDB:5I4N}.
FT   TURN        747    750       {ECO:0000244|PDB:5I4N}.
FT   TURN        753    756       {ECO:0000244|PDB:5I4N}.
FT   HELIX       759    767       {ECO:0000244|PDB:5I4N}.
FT   HELIX       778    780       {ECO:0000244|PDB:5I4N}.
FT   HELIX       781    787       {ECO:0000244|PDB:5I4N}.
FT   HELIX       792    794       {ECO:0000244|PDB:5I4N}.
FT   HELIX       798    807       {ECO:0000244|PDB:5I4N}.
FT   STRAND      836    838       {ECO:0000244|PDB:4E4M}.
FT   HELIX       846    848       {ECO:0000244|PDB:3UGC}.
FT   STRAND      849    857       {ECO:0000244|PDB:3UGC}.
FT   STRAND      859    868       {ECO:0000244|PDB:3UGC}.
FT   STRAND      872    874       {ECO:0000244|PDB:4IVA}.
FT   STRAND      877    885       {ECO:0000244|PDB:3UGC}.
FT   HELIX       889    903       {ECO:0000244|PDB:3UGC}.
FT   STRAND      913    917       {ECO:0000244|PDB:3UGC}.
FT   HELIX       919    922       {ECO:0000244|PDB:3UGC}.
FT   STRAND      926    930       {ECO:0000244|PDB:3UGC}.
FT   HELIX       937    943       {ECO:0000244|PDB:3UGC}.
FT   HELIX       945    947       {ECO:0000244|PDB:3UGC}.
FT   HELIX       950    969       {ECO:0000244|PDB:3UGC}.
FT   HELIX       979    981       {ECO:0000244|PDB:3UGC}.
FT   STRAND      982    986       {ECO:0000244|PDB:3UGC}.
FT   STRAND      989    992       {ECO:0000244|PDB:3UGC}.
FT   HELIX       995    997       {ECO:0000244|PDB:4D1S}.
FT   STRAND     1006   1009       {ECO:0000244|PDB:4IVA}.
FT   HELIX      1017   1020       {ECO:0000244|PDB:3UGC}.
FT   HELIX      1023   1028       {ECO:0000244|PDB:3UGC}.
FT   STRAND     1030   1032       {ECO:0000244|PDB:4IVA}.
FT   HELIX      1033   1049       {ECO:0000244|PDB:3UGC}.
FT   HELIX      1053   1055       {ECO:0000244|PDB:4IVA}.
FT   HELIX      1057   1065       {ECO:0000244|PDB:3UGC}.
FT   STRAND     1069   1071       {ECO:0000244|PDB:5HEZ}.
FT   HELIX      1072   1083       {ECO:0000244|PDB:3UGC}.
FT   TURN       1084   1086       {ECO:0000244|PDB:5HEZ}.
FT   HELIX      1096   1105       {ECO:0000244|PDB:3UGC}.
FT   HELIX      1110   1112       {ECO:0000244|PDB:3UGC}.
FT   HELIX      1116   1128       {ECO:0000244|PDB:3UGC}.
SQ   SEQUENCE   1132 AA;  130674 MW;  C30669EF1A7DA80C CRC64;
     MGMACLTMTE MEGTSTSSIY QNGDISGNAN SMKQIDPVLQ VYLYHSLGKS EADYLTFPSG
     EYVAEEICIA ASKACGITPV YHNMFALMSE TERIWYPPNH VFHIDESTRH NVLYRIRFYF
     PRWYCSGSNR AYRHGISRGA EAPLLDDFVM SYLFAQWRHD FVHGWIKVPV THETQEECLG
     MAVLDMMRIA KENDQTPLAI YNSISYKTFL PKCIRAKIQD YHILTRKRIR YRFRRFIQQF
     SQCKATARNL KLKYLINLET LQSAFYTEKF EVKEPGSGPS GEEIFATIII TGNGGIQWSR
     GKHKESETLT EQDLQLYCDF PNIIDVSIKQ ANQEGSNESR VVTIHKQDGK NLEIELSSLR
     EALSFVSLID GYYRLTADAH HYLCKEVAPP AVLENIQSNC HGPISMDFAI SKLKKAGNQT
     GLYVLRCSPK DFNKYFLTFA VERENVIEYK HCLITKNENE EYNLSGTKKN FSSLKDLLNC
     YQMETVRSDN IIFQFTKCCP PKPKDKSNLL VFRTNGVSDV PTSPTLQRPT HMNQMVFHKI
     RNEDLIFNES LGQGTFTKIF KGVRREVGDY GQLHETEVLL KVLDKAHRNY SESFFEAASM
     MSKLSHKHLV LNYGVCVCGD ENILVQEFVK FGSLDTYLKK NKNCINILWK LEVAKQLAWA
     MHFLEENTLI HGNVCAKNIL LIREEDRKTG NPPFIKLSDP GISITVLPKD ILQERIPWVP
     PECIENPKNL NLATDKWSFG TTLWEICSGG DKPLSALDSQ RKLQFYEDRH QLPAPKWAEL
     ANLINNCMDY EPDFRPSFRA IIRDLNSLFT PDYELLTEND MLPNMRIGAL GFSGAFEDRD
     PTQFEERHLK FLQQLGKGNF GSVEMCRYDP LQDNTGEVVA VKKLQHSTEE HLRDFEREIE
     ILKSLQHDNI VKYKGVCYSA GRRNLKLIME YLPYGSLRDY LQKHKERIDH IKLLQYTSQI
     CKGMEYLGTK RYIHRDLATR NILVENENRV KIGDFGLTKV LPQDKEYYKV KEPGESPIFW
     YAPESLTESK FSVASDVWSF GVVLYELFTY IEKSKSPPAE FMRMIGNDKQ GQMIVFHLIE
     LLKNNGRLPR PDGCPDEIYM IMTECWNNNV NQRPSFRDLA LRVDQIRDNM AG
//
